Ray Dalio's NBIX Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 149,990 shares of Neurocrine Biosciences, Inc. (NBIX) worth $21.27 M, representing 0.08% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in NBIX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 197,412 shares. Largest reduction occurred in Q1 2025, reducing 245,360 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Neurocrine Biosciences (NBIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Neurocrine Biosciences (NBIX) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +126,952 | Add 551.05% | 149,990 | $141.83 |
| Q3 2025 | +14,095 | Add 157.61% | 23,038 | $140.38 |
| Q2 2025 | -78,295 | Reduce 89.75% | 8,943 | $125.69 |
| Q1 2025 | -245,360 | Reduce 73.77% | 87,238 | $110.60 |
| Q4 2024 | +197,412 | Add 146.03% | 332,598 | $136.50 |
| Q3 2024 | +47,638 | Add 54.41% | 135,186 | $115.22 |
| Q2 2024 | +64,397 | Add 278.16% | 87,548 | $137.67 |
| Q1 2024 | -354 | Reduce 1.51% | 23,151 | $137.92 |
| Q4 2023 | -31,490 | Reduce 57.26% | 23,505 | $131.76 |
| Q3 2023 | -170 | Reduce 0.31% | 54,995 | $112.50 |
| Q2 2023 | -4,045 | Reduce 6.83% | 55,165 | $94.30 |
| Q1 2023 | +59,210 | New Buy | 59,210 | $101.22 |
| Q3 2022 | -6,503 | Sold Out | 0 | $0.00 |
| Q2 2022 | +1,483 | Add 29.54% | 6,503 | $97.49 |
| Q1 2022 | +2,493 | Add 98.65% | 5,020 | $93.82 |
| Q4 2021 | -670 | Reduce 20.96% | 2,527 | $85.08 |
| Q3 2021 | -2,737 | Reduce 46.12% | 3,197 | $96.03 |
| Q2 2021 | +5,934 | New Buy | 5,934 | $97.24 |
Ray Dalio's Neurocrine Biosciences Investment FAQs
Ray Dalio first purchased Neurocrine Biosciences, Inc. (NBIX) in Q2 2021, acquiring 5,934 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Neurocrine Biosciences, Inc. (NBIX) for 18 quarters since Q2 2021.
Ray Dalio's largest addition to Neurocrine Biosciences, Inc. (NBIX) was in Q4 2024, adding 332,598 shares worth $45.4 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 149,990 shares of Neurocrine Biosciences, Inc. (NBIX), valued at approximately $21.27 M.
As of the Q4 2025 filing, Neurocrine Biosciences, Inc. (NBIX) represents approximately 0.08% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Neurocrine Biosciences, Inc. (NBIX) was 332,598 shares, as reported at the end of Q4 2024.